<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940511-2-00212</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Comments received by May 26, 1994, will be reproduced and distributed to the Recombinant DNA Advisory Committee for consideration at its June 9&hyph;10, 1994, meeting. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> <!-- PJG FTAG 4717 -->  <!-- PJG STAG 4717 -->  <!-- PJG ITAG l=01 g=1 f=1 --> Wednesday <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=02 g=1 f=1 --> May 11, 1994 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=03 g=1 f=1 --> Part IX <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Department of Health and Human Services <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> National Institutes of Health <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> Recombinant DNA Research: Proposed Actions Under the Guidelines; Notice <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG -->  <!-- PJG /FTAG -->  <!-- PJG FTAG 4701 -->  <!-- PJG STAG 4701 -->  <!-- PJG ITAG l=90 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=1 --> &blank;/&blank;Vol. 59, No. 90&blank;/&blank;Wednesday, May 11, 1994&blank;/&blank;Notices <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Recombinant DNA Research: Proposed Actions Under the Guidelines <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> National Institutes of Health, PHS, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice of proposed actions under the NIH guidelines for research involving recombinant DNA molecules (51 FR 16958). <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> This notice sets forth proposed actions to be taken under the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules (51 FR 16958). Interested parties are invited to submit comments concerning these proposals. These proposals will be considered by the Recombinant DNA Advisory Committee at its meeting on June 9&hyph;10, 1994. After consideration of these proposals and comments by the Recombinant DNA Advisory Committee, the Director of the National Institutes of Health will issue decisions in accordance with the NIH Guidelines. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Comments received by May 26, 1994, will be reproduced and distributed to the Recombinant DNA Advisory Committee for consideration at its June 9&hyph;10, 1994, meeting. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Written comments and recommendations should be submitted to Dr. Nelson A. Wivel, Director, Office of Recombinant DNA Activities (ORDA), building 31, room 4B11, National Institutes of Health, Bethesda, Maryland 20892, or sent by FAX to 301&hyph;496&hyph;9839. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> All comments received in timely response to this notice will be considered and will be available for public inspection in the above office on weekdays between the hours of 8:30 a.m. and 5 p.m. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Background documentation and additional information can be obtained from the Office of Recombinant DNA Activities, building 31, room 4B11, National Institutes of Health, Bethesda, Maryland 20892, (301) 496&hyph;9838. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The NIH will consider the following actions under the NIH Guidelines for Research Involving Recombinant DNA Molecules: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> I. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene Transfer Protocol/Drs. Sobol and Royston <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In a letter dated October 6, 1993, Drs. Robert Sobol and Ivor Royston of the San Diego Regional Cancer Center, San Diego, California, submitted the human gene transfer protocol entitled: Injection of Glioblastoma Patients with Tumor Cells Genetically Modified to Secrete Interleukin-2 (IL&hyph;2): A Phase I Study to the Recombinant DNA Advisory Committee for formal review and approval. At the December 2&hyph;3, 1993, meeting, the Recombinant DNA Advisory Committee disapproved the original protocol. The majority of the Recombinant DNA Advisory Committee members concluded that the preclinical data derived from a previous single patient protocol was inadequate to justify the experiment. The motion to disapprove the protocol passed by a vote of 10 in favor, 5 opposed, and 1 abstention. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <!-- PJG /STAG -->  <!-- PJG /FTAG --></p>
		</main>
</body></html>
            